International Consensus on Standardized Clinic Blood Pressure Measurement – A Call to Action - 01/05/23

Esquema
| Funding: None. |
|
| Conflicts of Interest: AKC declared having received consultancy fees from Boehringer Ingelheim; he reported having served on an expert committee for Boehringer Ingelheim; and has stock/stock options in Merck. AES declared having received speaker honoraria from Omron Healthcare and Aktiia. BW declared having received research support and speaker honoraria from Omron Cooperation*. PS declared having received research support from Elpen Pharmaceuticals* and Servier*; he declared having received consultancy fees from Primeview* and ReCor Medical*; and declared having received speaker honoraria from Sanofi* and Winmedica*. TIC declared having received consultancy fees from George Clinical, Gilead*, Novo Nordisk, and Bayer*; she reported having served on an expert committee for AstraZeneca, and Bayer. SSD declared having received speaker honoraria from Servier. RK declared having received speaker honoraria from Bayer, Berlin-Chemie, Daiichi-Sankyo, Ferrer, Menarini, Merck, Sanofi, and Servier. JMF declared having received research support from GlaxoSmithKline, Indorsia, Quantum Genomics, ReCor Medical, and Vascular Dynamics; he declared having received consultancy fees from ReCor Medical and Sanofi; he reported having received payment for expert testimony from Teva; he reported having served on an expert committee for Amgen, Fibrogen, and Janssen; and has stock/stock options in Amphastar and CVS. GM declared having received speaker honoraria from Boehringer Ingelheim, Gedeon Richter, Medtronic, Menarini, Merck, Sandoz, Sanofi, and Servier. PO is staff member of the Pan American Health Organization (PAHO). The authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of PAHO. RP declared being the Chief Executive Officer at mmHg, Inc. AP declared having received research support from Ablative Solutions, Quantum Genomics, Recor Medical, and Servier; he reported having served on an expert committee for Ablative Solutions and Quantum Genomics. MS declared having received research support from Abbott, Idorsia, Medtronic, Metavention, ReCor; he reported having received speaker honoraria from Abbott, Medtronic, and ReCor; and support for travel from Medtronic*. GSS declared having received research support from Braun*, InBody*, and Microlife*; he declared having received consultancy fees from Huawei, InBody, and Microlife. SWT declared having received consultancy fees from AstraZeneca*; he declared having received speaker honoraria from Amgen*, AstraZeneca*, BMS*, Bayer*, Boehringer Ingelheim*, Janssen*, Eli Lily and Company*, Novartis*, Novo Nordisk*, Pfizer*, and Sanofi-Genzyme*. JFEM declared having received research support from Novo Nordisk; he declared having received consultancy fees from AstraZeneca, Boehringer Ingelheim, Bayer, and Novartis; and declared having received speaker honoraria from AstraZeneca, Bayer, Fresenius, Novartis, and Novo Nordisk. All the other authors declared no competing interests. *Monies paid to institution. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 136 - N° 5
P. 438 - mai 2023 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
